Dwan, K, Gamble, C, Williamson, PR and Kirkham, JJ (2013) Systematic review of the empirical evidence of study publication bias and outcome reporting bias – an updated review. PLoS ONE 8, e66844.
Ebrahim, S, Bance, S, Athale, A, Malachowski, C and Ioannidis, JPA (2015) Meta-analyses with industry involvement are massively published and report no caveats for antidepressants. Journal of Clinical Epidemiology 70, 155–163.
Fanelli, D (2012) Negative results are disappearing from most disciplines and countries. Scientometrics 90, 891–904.
Golden, RN, Nemeroff, CB, McSorley, P, Pitts, CD and Dubé, EM (2002) Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. The Journal of Clinical Psychiatry 63, 577–584.
Hammad, TA, Laughren, TP and Racoosin, J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 63, 332–339.
Hart, B, Lundh, A and Bero, L (2012) Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. British Medical Journal 344, d7202.
Le Noury, J, Nardo, JM, Healy, D, Jureidini, J, Raven, M, Tufanaru, C and Abi-Jaoude, E (2015) Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. British Medical Journal 351, h4320.
McGauran, N, Wieseler, B, Kreis, J, Schüler, Y-B, Kölsch, H and Kaiser, T (2010) Reporting bias in medical research – a narrative review. Trials 11, 37.
Melander, H, Ahlqvist-Rastad, J, Meijer, G and Beermann, B (2003) Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. British Medical Journal 326, 1–5.
Miller, SM, Naylor, GJ, Murtagh, M and Winslow, G (1989) A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta Psychiatrica Scandinavica Supplementum 350, 143–144.
Rising, K, Bacchetti, P and Bero, L (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Medicine 5, 1561–1570.
Roest, AM, de Jonge, P, Williams, CD, de Vries, YA, Schoevers, RA and Turner, EH (2015) Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 meta-analyses. JAMA Psychiatry 72, 500–510.
Saini, P, Loke, YK, Gamble, C, Altman, DG, Williamson, PR and Kirkham, JJ (2014) Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. British Medical Journal 349, g6501.
Settle, EC, Stahl, SM, Batey, SR, Johnston, JA and Ascher, JA (1999) Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clinical Therapeutics 21, 454–463.
Sismondo, S (2009) Ghosts in the machine: publication planning in the medical sciences. Social Studies of Science 39, 171–198.
Smith, R (2005) Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine 2, e138.
Spielmans, GI and Parry, PI (2010) From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Journal of Bioethical Inquiry 7, 13–29.
Spielmans, GI, Biehn, TL and Sawrey, DL (2010) A case study of salami slicing: pooled analyses of duloxetine for depression. Psychotherapy and Psychosomatics 79, 97–106.
Spielmans, GI, Olson, S and Keicher, RM (2017) ‘Salami slicing’ in pooled analyses of second-generation antipsychotics for the treatment of depression. Psychotherapy and Psychosomatics 55108, 171–172.
Stone, M, Laughren, TP, Jones, ML, Levenson, M, Holland, PC, Hughes, A, Hammad, TA, Temple, R and Rochester, G (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. British Medical Journal 339, b2880.
Thaler, KJ, Morgan, LC, Van Noord, M, Jonas, DE, McDonagh, MS, Peterson, K, Glechner, A and Gartlehner, G (2013) A case study of pooled-studies publications indicated potential for both valuable information and bias. Journal of Clinical Epidemiology 66, 1082–1092.
The PLoS Medicine Editors (2009) Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Medicine 6, e1000156.
Turner, EH (2004) A taxpayer-funded clinical trials registry and results database. PLoS Medicine 1, e60.
Turner, EH (2013 a) How to access and process FDA drug approval packages for use in research. British Medical Journal 347, f5992.
Turner, EH (2013 b) Publication bias, with a focus on psychiatry: causes and solutions. CNS Drugs 27, 457–468.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA and Rosenthal, R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358, 252–260.
Turner, EH, Knoepflmacher, D and Shapley, L (2012) Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Medicine 9, e1001189.
Vedula, SS, Goldman, PS, Rona, IJ, Greene, TM and Dickersin, K (2012) Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation. Trials 13, 1–13.